GSK to Partner with Massachusetts Biotech Vesalius on Parkinson Drug Development Effort
- November 15, 2024
GlaxoSmithKline is entering into a “multi-target strategic alliance” with Massachusetts-based biotech Vesalius Therapeutics to develop novel treatments for Parkinson’s disease and another undisclosed neurodegenerative indication, according to a November 8 press release.
ARTICLE TAGS
You must be logged in to access this content.